This trial is also designed to assess belzutifan efficacy on VHL-related pheochromocytomas and paragangliomas, a VHL manifestation that was not previous evaluated under belzutifan treatment [37]. This evidence concerns the gene VHL and hereditary pheochromocytoma-paraganglioma.